follistatin-344: the myostatin-antagonist research peptide

follistatin-344 is a splice variant of the human follistatin gene that produces the circulating FS-315 protein, a high-affinity antagonist of myostatin, activin A, and GDF11. it became famous in muscle-biology research as the construct that drove durable hypertrophy in AAV gene-therapy studies and, later, the first follistatin trial in humans.

what is follistatin-344?

follistatin is a secreted glycoprotein the body uses to fine-tune TGF-beta superfamily signaling. the human gene produces two pre-mRNA splice variants, FS-344 (which yields the longer 315-residue circulating protein) and FS-317 (which yields the shorter 288-residue tissue-anchored form). FS-344 is the variant used in essentially all modern gene-therapy work because it produces a protein that travels in the blood.

the FS-315 product of FS-344 splicing has an acidic C-terminal tail that prevents it from sticking to heparan sulfate on cell surfaces, so it circulates freely in plasma. the FS-288 product of FS-317 splicing lacks that tail, binds heparan sulfate avidly, and is therefore largely sequestered at tissue surfaces. from a drug-design point of view this means a single splice choice determines whether the protein acts systemically or locally [1].

follistatin binds myostatin (GDF8) with picomolar affinity, and it also neutralizes activin A and GDF11. because myostatin is the dominant negative regulator of skeletal muscle mass in mammals (the gene whose loss creates "double-muscled" cattle and the famous myostatin-null human child), an inhibitor that mops up circulating myostatin has long been an obvious therapeutic target for muscle-wasting disease [2].

how does it work?

myostatin normally binds the activin type 2B receptor on muscle cells and turns on a SMAD2/3 cascade that suppresses growth and pushes muscle protein toward breakdown. follistatin neutralizes myostatin in the bloodstream before it can reach the receptor, lifting that brake and tilting the balance toward hypertrophy. it does the same for activin A and GDF11 because those ligands engage the same receptor family.

in a follistatin-overexpressing transgenic mouse model published by Zhu and colleagues in The American Journal of Pathology in 2011, muscle injury healed with significantly greater myofiber regeneration and less fibrosis than in wild-type littermates, consistent with the dual pro-regeneration and anti-fibrotic effect predicted by myostatin and activin neutralization [3]. Rodgers and Garikipati's comparative review in Endocrine Reviews in 2008 captures the broader biology: myostatin is conserved across vertebrates, and its loss-of-function consistently produces a muscle-mass increase that is large, durable, and largely free of obvious functional cost in young animals [2].

the practical problem with myostatin biology is that the same TGF-beta receptors that myostatin uses are also used by activin A in reproduction and hematopoiesis and by GDF11 in tissue patterning. a recent review by Wetzlich and colleagues in Molecular and Cellular Biochemistry in 2024 spells out why so many pharmaceutical myostatin inhibitors have failed in clinical trials despite strong preclinical signals: serum myostatin in humans is much lower than in mice, the muscle response requires neural input that drug studies often did not control for, and selectivity for myostatin versus activin A is harder to achieve than animal data implied [4]. follistatin sits inside that selectivity problem because, by design, it is a multi-target antagonist.

what does the evidence show?

the strongest preclinical evidence for FS-344 comes from a 2008 PNAS paper by Haidet and colleagues that showed AAV1 delivery of FS-344 produced durable muscle mass and strength gains lasting more than two years in normal and dystrophic mice. the strongest human evidence is a 2017 six-patient gene-therapy trial in sporadic inclusion body myositis that produced functional gains and reduced fibrosis on biopsy.

the Haidet paper in the Proceedings of the National Academy of Sciences tested four myostatin-inhibitor constructs delivered by a single intramuscular AAV1 injection. the paper explicitly singles out FS-344 as the variant producing the greatest effect, and the muscle-mass and strength benefit was still measurable two years after a single injection [5]. that durability is the property that made FS-344 the lead construct for clinical translation.

the Mendell group at Nationwide Children's Hospital ran the first human trial in Molecular Therapy in 2017. six ambulatory patients with sporadic inclusion body myositis received bilateral quadriceps injections of AAV1 carrying FS-344. treated patients gained roughly 56 meters per year on the six-minute walk test while matched untreated controls declined, and muscle biopsies showed reduced fibrosis and signs of regeneration [6]. the trial was a small proof-of-concept, not a Phase 3 program, and it has not been followed by a registration study.

adjacent preclinical evidence has continued to accumulate. Giesige and colleagues in JCI Insight in 2018 showed AAV1-delivered follistatin significantly increased muscle mass and strength in a tamoxifen-inducible DUX4 mouse model of facioscapulohumeral muscular dystrophy [7]. Rodino-Klapac and colleagues in Human Molecular Genetics in 2013 showed that combining micro-dystrophin gene therapy with follistatin restored eccentric-contraction resistance in aged dystrophic mice better than either treatment alone [8]. the through-line is that follistatin-344 produces consistent preclinical benefit; the gap is large randomized human data.

regulatory and research status

follistatin-344 has no FDA approval for any indication. the only registered human program of any size has been the Nationwide Children's AAV-FS-344 work in sporadic inclusion body myositis. compounded synthetic follistatin peptides sold online for muscle gain do not match the gene-therapy construct used in those trials and have no human controlled-trial evidence behind them.

it is worth being precise about what "follistatin-344" means in different contexts. in the gene-therapy literature it refers to the FS-344 splice variant cDNA packaged inside AAV1 and injected directly into muscle. in research-peptide e-commerce it often refers to a synthetic protein or fragment produced by chemical synthesis or bacterial expression, sold as "research-use only" without controlled-trial efficacy or safety data. the two are not interchangeable, and most of the preclinical literature on this page describes the gene-therapy construct.

follistatin is also on the World Anti-Doping Agency prohibited list under category S4.5 ("myostatin function inhibitors") at all times. any competitive athlete in a WADA-tested sport should be aware that use is banned in and out of competition.

safety considerations

in the small human gene-therapy experience to date, follistatin-344 has been generally well tolerated, with the most concerning theoretical risks coming from its off-target activity against activin A and GDF11 rather than from myostatin blockade itself. extended human safety data simply do not yet exist.

in the Mendell sporadic inclusion body myositis trial, no significant adverse events attributable to AAV1-FS-344 were reported through the published follow-up, although the sample size was six [6]. the broader concern, articulated in the Wetzlich review, is that follistatin's known activity against activin A and GDF11 could in principle affect reproductive endocrinology, hematopoiesis, and tissue-repair programs that depend on those ligands [4]. none of those signals have appeared in the published human dataset, but the dataset is small and short.

a separate practical concern with AAV gene therapy is that the body can mount neutralizing antibodies against the viral capsid, which limits redosing. this matters because follistatin therapy is intended to be durable, and any decline in transgene expression cannot be easily rescued with a second injection of the same serotype. synthetic peptide formulations sold under the "follistatin" label avoid this constraint but lose the durability that gene therapy provides.

where it fits in peptide research

follistatin-344 sits at the center of a small family of myostatin-pathway therapeutics that includes monoclonal antibodies (domagrozumab, landogrozumab), receptor-blocking constructs, and follistatin-Fc fusion proteins. it is the most directly studied member of that family in published gene-therapy work, but the broader category has a long history of preclinical promise and clinical disappointment.

the natural comparison is with other GH-axis tools we cover, including tesamorelin, which acts upstream through the GHRH receptor to raise IGF-1. the two mechanisms are not redundant: tesamorelin amplifies anabolic drive through the GH-IGF-1 axis, while follistatin removes the myostatin brake on muscle protein synthesis. whether they would combine usefully in humans has not been studied in controlled trials.

a useful primer on the wider category of muscle-targeted peptides is our muscle-building peptides guide, and our vetting research peptides guide covers how to evaluate any compound sold under a research-use-only label. for the underlying biology of how peptides interact with receptors and feedback loops, see the free peptides and your body module.